A drug developed to treat cancer may protect the liver from obesity. This has been shown by a study published in the journal. PNAS.
The drug MLN4924 (Pevonedistat) was developed to treat cancer. Previous studies have shown that in addition to killing cancer cells, it also prevents the destruction of the protein cullin-3, which is necessary for all cells to respond to insulin surges. In a new experiment on genetically modified mice, scientists showed that this effect protected the mice’s livers from fat accumulation.
Although the animals avoided liver disease, fat began to accumulate in their muscles. As a result, the muscles, the largest organ in the body, became less sensitive to insulin. At the same time, the mice’s blood sugar levels also increased. This means that fat metabolism in muscle and liver are interconnected.
Scientists suggest that treating fatty liver disease requires simultaneous work on losing weight and increasing the body’s sensitivity to insulin. They believe Pevonedistat is a promising candidate for the treatment of fatty liver disease. The study also shows why treating chronic conditions like type 2 diabetes and fatty liver disease is never easy: Improvements in one area can have negative effects in another.
Russians before saidHow do you protect your liver while taking medication?
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.